Vascular Graft Solutions (VGS) revealed on Monday that it has acquired several patent families from NEOGRAFT Technologies Inc, including patents previously developed and owned by venous external stenting and vascular engineering company Kipsbay Medical Inc.

VGS said the acquired portfolio of patents include over 25 patents in the US, Europe, Canada and Japan, which will broaden its existing portfolio and protection on its unique suite of technologies developed and commercialised for coronary bypass, peripheral vascular reconstruction and repair of high flow AV fistula in dialysis patients.

Eyal Orion, founder and CEO of VGS, stated: "Strengthening our IP portfolio, coupled with the evolution of our clinical data, position VGS as a global leader in the field of advanced vascular engineering. We continue to be committed to patients with cardiovascular diseases and invest significant resources to develop novel solutions that will improve cardiovascular surgery and patient' outcome. The new patents and know-how, which are based on the extensive research done by the renowned cardiac surgeon Prof Peter Zilla and his team from Cape Town, will enable us to explore new approaches to create blood vessel which are resistant to the development of atherosclerosis."

Headquartered in Tel-Aviv, Israel, VGS has distribution channels around Europe, South Africa, Mexico and Australia.